Real Life Sciences' November Newsletter for Singapore

The most recent one that has a huge impact on the industry would be the acquisition of Abbott Medical Optics by Johnson & Johnson. As two giants within the pharmaceutical industry, any acquisition affects both large and small players in the market. Things are looking such that the optical market would now be highly dominated by Johnson & Johnson Vision Care.

Closer to home would be the restructure of research operations for Novartis. With the shift of research facility from Singapore to the US, this will cut significant costs for Novartis as their research operations are now centralised and made easier for future collaborative efforts. Novartis has also reduced the number of jobs within their organisation with this shift and a closure of one of their business units - Biologics Group in Shanghai. Asia can however find comfort in the assurance that Novartis is ranked 4th in the pharmaceutical companies of 2016 based on 2015's revenue and has promised its continual investment within Singapore as well as China.

For more details of the above mentioned as well as other industry bites, please click here to download the full version of the newsletter.